Interleukin-6 Gene Promoter-572 C Allele May Play a Role in Rate of Disease Progression in Multiple Sclerosis

by Judith M. Greer, Australia & New Zealand Multiple Sclerosis Genetics Consortium (ANZGene), Pamela A. McCombe, Michael P. Pender, Peter A. Csurhes, Clement Yihao Lin, Jia Liu, Jun Yan
Published 2012-10-01

Sustained Clinical Improvement in a Subset of Patients With Progressive Multiple Sclerosis Treated With Epstein–Barr Virus-Specific T Cell Therapy

by Zara A. Ioannides, Zara A. Ioannides, Zara A. Ioannides, Peter A. Csurhes, Peter A. Csurhes, Nanette L. Douglas, Nanette L. Douglas, Nanette L. Douglas, Gem Mackenroth, Gem Mackenroth, Gem Mackenroth, Andrew Swayne, Andrew Swayne, Andrew Swayne, Kate M. Thompson, Kate M. Thompson, Tracey J. Hopkins, Kerryn A. Green, Kerryn A. Green, Stefan Blum, Stefan Blum, Stefan Blum, Kaye D. Hooper, Kaye D. Hooper, Kaye D. Hooper, Kerstin H. Wyssusek, Kerstin H. Wyssusek, Alan Coulthard, Alan Coulthard, Michael P. Pender, Michael P. Pender
Published 2021-03-01

Epstein-Barr virus–specific T cell therapy for progressive multiple sclerosis

by Michael P. Pender, Peter A. Csurhes, Corey Smith, Nanette L. Douglas, Michelle A. Neller, Katherine K. Matthews, Leone Beagley, Sweera Rehan, Pauline Crooks, Tracey J. Hopkins, Stefan Blum, Kerryn A. Green, Zara A. Ioannides, Andrew Swayne, Blake T. Aftab, Kaye D. Hooper, Scott R. Burrows, Kate M. Thompson, Alan Coulthard, Rajiv Khanna
Published 2020-10-01